Johnson & Johnson to report Q2 earnings on July 16. Here’s what to expect
Johnson & Johnson’s (NYSE: JNJ) business strategy for fiscal 2025 is focused on reducing the impact of patent expirations on its revenue. Anticipating sales to benefit from growth initiatives, including acquisitions and product rollouts, the company has raised its full-year revenue guidance. Meanwhile, the business is under pressure from multiple talc-related lawsuits, with potential liabilities … Read more